Cell-and-Gene Patient-Custody Board Challenger

The mandate

The committee keeps returning to whether a digitally complete chain-of-identity record proves that the correct patient material remained physically controlled from scheduling and apheresis through manufacturing, cryogenic return and infusion. Treatment centres, couriers and production teams can each close their own handover while a missed collection, slot change, relabel, shipper intervention or patient deterioration creates a gap between identity certainty and an executable treatment plan. Directors need assurance at the patient boundary, not another platform dashboard.

Patient-custody work is organised within a three-day monthly retainer. One block reconstructs case evidence, another conducts the single cross-network challenge, and the remaining time prepares the chair and closes agreed actions. The adviser will join six quality-and-patient-safety committee sessions and observe four treatment-centre, courier or manufacturing interfaces. For a serious custody deviation, the first risk framing is due inside twelve hours and the documented challenge no later than the second United States business day. That service level never transfers a live clinical or batch decision from its authorised professional.

Ten months are deliberately bounded by two manufacturing-capacity peaks and the disrupted-patient exercise. Closeout requires management to run the patient-custody review without the adviser and receive the unresolved-case ledger; any open deviation or delayed market launch stays with its accountable owner rather than carrying advisory time forward. Unused observations expire. Only a fresh committee vote on a materially different assurance question, accompanied by renewed conflict declarations, can commission further service.

The adviser has no line authority and carries no executive responsibility for patient selection, clinical care, collection, transport release, manufacturing slot assignment, batch disposition, infusion or regulatory reporting. Treating clinicians, qualified quality personnel and accountable executives retain those powers. The adviser may challenge whether evidence supports a claimed safe handover and press for board conditions, but cannot identify a patient publicly or order a treatment delay.

Work for competing therapy developers, treatment-centre networks, apheresis firms, specialist couriers, cryogenic packaging vendors, contract manufacturers or custody-platform suppliers must be disclosed. A relevant conflict requires recusal from the entire product or counterparty case. Compensation cannot depend on treated-patient volume, batch release, launch timing, provider selection or a later remediation engagement, and paid introductions are prohibited.

Why the board wants this voice

Quality sees batch control, patient services see schedules, logistics sees shipments and clinicians see treatment readiness, but no current director has run the entire vein-to-vein operating chain at scale. The board wants someone able to spot when each function is locally correct and the patient outcome is still exposed. Independent challenge must strengthen named executives rather than create a shadow release or clinical authority.

What you will own

• Press management to trace identity, custody, condition, slot and patient-readiness decisions through complete vein-to-vein cases.
• Test collection and manufacturing reservations against courier cut-offs, cryogenic endurance, capacity changes and treatment-centre preparedness.
• Challenge digital closure where label, seal, shipper, person, time or physical-location evidence remains contradictory or inferred.
• Probe patient reschedule, failed collection, missed flight, manufacturing deviation and return-delay playbooks for executable choices.
• Observe four network interfaces and distinguish procedural compliance from a handover another party can actually accept.
• Shape board thresholds for custody deviation, treatment-centre restriction, launch expansion and independent escalation without directing execution.
• Give the chair an anonymised casebook, boundary map, conflict register and annual patient-custody assurance agenda.

Candidate qualifications

• Held global patient-supply, quality or operations authority for autologous cell therapy, gene therapy or similarly personalised products.
• Has managed chain-of-identity risk across collection, courier, manufacturing, cryogenic return and treatment-centre receipt in live cases.
• Understands patient scheduling, manufacturing slots, labels, seals, shippers, custody events and clinical readiness as linked controls.
• Can challenge a custody conclusion without assuming clinician, qualified-person, privacy, regulator or logistics-provider authority.
• Has handled patient-specific exceptions where digital records appeared complete but the physical treatment chain was not executable.
• Advised senior quality and commercial leaders while protecting patient confidentiality and maintaining independence from network vendors.

Non-negotiables

• Can attend six Boston committee sessions and complete four treatment-centre, courier or manufacturing observations.
• Will disclose therapy-developer, treatment-centre, courier, packager, manufacturer and custody-platform relationships before access.
• Brings direct vein-to-vein operating experience; generic pharmaceutical cold-chain assurance alone is insufficient.
• Accepts no patient, clinical, slot, transport-release, batch-disposition, infusion, reporting or board-voting authority.

1. 49 words maximum. Describe a patient chain where complete system events concealed a physical custody or readiness gap.
2. 49 words maximum. Which therapy, centre, courier or manufacturer relationship could require your recusal?
3. 49 words maximum. What evidence must survive when a manufacturing slot moves after apheresis is already scheduled?